inavolisib

Drug Overview

Inavolisib is a highly specialized cancer medication designed to treat specific types of advanced breast cancer. It belongs to a group of modern medicines known as Targeted Therapy. Unlike traditional chemotherapy, which affects all fast-growing cells in the body, targeted therapies are “smart drugs” that focus specifically on the unique parts of cancer cells that help them survive and grow. By targeting these specific areas, inavolisib aims to stop the tumor from spreading while trying to limit the damage to healthy cells.

This medication is used in combination with two other drugs, palbociclib and fulvestrant, to provide a strong, multi-layered defense against cancer progression. It is prescribed for adult patients whose tumors have a specific genetic change (mutation) and who have stopped responding to standard hormone therapies.

Here are the key details about this medication:

• Generic Name: inavolisib
• US Brand Name: Itovebi
• Drug Class: Kinase Inhibitor / Phosphatidylinositol 3-kinase (PI3K) alpha inhibitor (Targeted Therapy)
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: FDA-approved for standard clinical use as of October 10, 2024.

What Is It and How Does It Work? (Mechanism of Action)

To understand how inavolisib works, it is helpful to look at how cells communicate. Inside our cells, there are signaling pathways. Think of these pathways as a relay race, where proteins pass messages to each other telling the cell to grow, divide, or survive. One of the most important pathways is the PI3K/AKT/mTOR pathway.

In some breast cancers, there is a mutation (error) in a gene called PIK3CA. This gene is responsible for making a protein called PI3K alpha. When the PIK3CA gene is mutated, the PI3K alpha protein becomes overactive. It acts like a switch that is stuck in the “on” position, constantly telling the cancer cells to multiply and hide from the body’s natural defenses.

Inavolisib is a Targeted Therapy designed to fix this specific problem at the molecular level. It works through a powerful, dual-action mechanism:

1. Blocking the Signal: After a patient swallows the pill, the drug travels through the bloodstream and enters the cancer cells. It specifically seeks out the mutated PI3K alpha enzyme. Once it finds it, inavolisib binds tightly to the enzyme’s active site, acting like a physical block. This prevents the enzyme from creating a molecule called PIP3, which cuts off the signals that tell the cancer cell to grow.
2. Destroying the Target: Inavolisib does not just block the enzyme; it actually triggers the cell’s natural garbage disposal system. It marks the mutated PI3K alpha protein for destruction, causing the mutant protein to break down completely.

By both blocking and destroying this mutant protein, inavolisib effectively shuts down the cancer cell’s power supply, leading to the death of the tumor cells.

FDA Approved Clinical Indications

Currently, inavolisib is approved for specific cancer treatments. It does not have non-oncological (non-cancer) uses at this time.

Oncological Uses

Inavolisib is FDA-approved for the treatment of adult patients with:

• Breast cancer that is hormone receptor (HR)-positive.
• Breast cancer that is human epidermal growth factor receptor 2 (HER2)-negative.
• Breast cancer that has a PIK3CA mutation (as detected by an FDA-approved test).
• Locally advanced or metastatic breast cancer (cancer that has spread to nearby tissue or other parts of the body).
• Cancer that is endocrine-resistant (meaning the disease has worsened during or after previous hormone-based therapies).

Note: Inavolisib is approved to be used in combination with palbociclib and fulvestrant, not as a standalone treatment.

Non-oncological Uses

• None at this time.

Dosage and Administration Protocols

Because inavolisib is an oral medication, it is taken daily by the patient at home. It is very important to take this medication exactly as prescribed by an oncologist.

Clinical Efficacy and Research Results

Recent clinical studies from 2020 to 2025 have shown that inavolisib is highly effective for patients with this specific genetic profile. The FDA approval was based on a major Phase 3 clinical trial called INAVO120.

This trial included 325 patients and compared the combination of inavolisib, palbociclib, and fulvestrant against a placebo (sugar pill) mixed with palbociclib and fulvestrant. The results demonstrated clear benefits for patients taking the inavolisib combination:

• Delaying Disease Progression: The trial measured Progression-Free Survival (PFS), which is how long a patient lives without their cancer getting worse. Patients taking inavolisib had a median PFS of 15.0 months, compared to only 7.3 months for those taking the placebo. This means the drug reduced the risk of the disease worsening or death by 57%.
• Overall Survival Rates: The study showed that inavolisib helped people live longer. The median Overall Survival (OS) was 34.0 months for the inavolisib group, compared to 27.0 months for the placebo group.
• Tumor Shrinkage: The Objective Response Rate (the percentage of patients whose tumors shrank significantly) was 62.7% in the inavolisib group, compared to just 28.0% in the placebo group.

These numerical data points prove that adding this “smart drug” to standard therapy creates a much stronger defense against tumor growth and significantly improves patient outcomes.

Safety Profile and Side Effects

Like all powerful cancer medications, inavolisib can cause side effects. Because this drug impacts how cells process energy, it has specific side effects that require careful monitoring.

While there is no official FDA “Black Box Warning,” the drug’s labeling carries severe warnings regarding high blood sugar, mouth sores, diarrhea, and risks to unborn babies.

Common Side Effects (>10% of patients)

• Increased fasting blood glucose (high blood sugar)
• Stomatitis (painful mouth sores, swelling, or redness)
• Diarrhea
• Fatigue and unusual tiredness
• Decreased appetite and weight loss
• Nausea
• Skin rash or dry skin
• Headache
• Laboratory changes: Decreased white blood cells (neutrophils and lymphocytes), decreased red blood cells (anemia), decreased platelets, and altered levels of calcium and potassium.

Serious Adverse Events

• Severe Hyperglycemia: This drug can cause dangerously high blood sugar levels, sometimes leading to a life-threatening condition called ketoacidosis.
• Severe Dehydration and Kidney Injury: This can happen if diarrhea becomes too severe and is left untreated.
• Embryo-Fetal Toxicity: Inavolisib can cause severe birth defects or loss of an unborn baby if taken during pregnancy.

Management Strategies

• For High Blood Sugar: Doctors will often prescribe anti-diabetic medications (like metformin or insulin) to manage blood sugar. Patients must monitor their blood sugar at home.
• For Mouth Sores: A special mouthwash containing a mild steroid (corticosteroid) is often prescribed to prevent or heal mouth ulcers.
• For Diarrhea: Patients are advised to drink large amounts of water to stay hydrated and take over-the-counter or prescription anti-diarrhea medications at the very first sign of loose stools.

Research Areas

Inavolisib, approved for breast cancer, shows promise beyond oncology by targeting mutated proteins. Researchers are investigating combining PI3K inhibitors with immunotherapy, as modulating the PI3K pathway may enhance tumor visibility to immune cells. No current link exists with stem cell therapies, but studies continue exploring potential future combinations with cell-based treatments.

Patient Management and Practical Recommendations

To ensure safety and get the best results from the treatment, patients and doctors must work as a team.

Pre-treatment Tests to be Performed

• Genetic Testing: An FDA-approved blood or tissue test to confirm the tumor has the PIK3CA mutation.
• Blood Sugar Check: Fasting blood glucose (FPG) and HbA1c tests to check for underlying diabetes.
• Pregnancy Test: A negative pregnancy test is strictly required for females of childbearing age before starting the drug.

Precautions During Treatment

• Blood sugar must be checked very frequently: once every 3 days for the first week, once a week for the next three weeks, and regularly after that.
• Both men and women of reproductive age must use highly effective, non-hormonal birth control during treatment and for at least one week after the final dose.
• Mothers should not breastfeed while taking this medication.

“Do’s and Don’ts” List

• DO check your blood sugar at home exactly as your doctor instructs.
• DO drink plenty of fluids every day to prevent dehydration.
• DO call your healthcare provider immediately if you feel very thirsty, need to urinate frequently, or have fruity-smelling breath, as these are signs of dangerously high blood sugar.
• DO start using a steroid mouthwash if recommended by your doctor to prevent mouth sores.
• DON’T ignore diarrhea. Start treatment and contact your doctor right away.
• DON’T take a double dose of your medication if you forget to take a pill.
• DON’T become pregnant or father a child while on this therapy.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. While inavolisib (Itovebi) is an FDA-approved therapy for specific indications, treatment plans must be highly personalized. Every patient’s medical history, tumor genetics, and risk for side effects are different. Always consult with a qualified healthcare professional or your treating oncologist regarding your exact diagnosis, treatment options, potential drug interactions, and eligibility for this targeted therapy.